[Synergism of sobuzoxane in combination with doxorubicin against leukemia P388 in mice].
作者信息
Dai Z Q, Xu J Y, Yuan X J, Cai J C
机构信息
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China.
出版信息
Zhongguo Yao Li Xue Bao. 1996 Jan;17(1):69-71.
AIM
To study the antitumor activity of sobuzoxane (Sob) in combination with doxorubicin (Dox) and the effect of Sob on Dox-induced cardiotoxicity.
METHODS
DBA/2 mice bearing transplanted leukemia P388 were given i.v. Dox 2 mg.kg-1.d-1 for 3 d, 4 mg.kg-1.d-1 for 1 d combined with ig Sob 20, 40 mg.kg-1.d-1 for 7 d. The increase in life span (ILS) of each group was recorded in 30 d. The myocardium of moribund mice was examined by transmission electron microscopy.
RESULTS
The ILS of combination therapeutic groups of Sob with Dox was 48.7%, 57.3%, 59.0%, and 62.4% respectively, which were 30%-90% higher than the sum of ILS of two groups treated with Dox and Sob separately (P < 0.01). The ultrastructural injury of cardiomyocytes of P388-bearing mice caused by combination chemotherapy with Dox plus Sob was markedly attenuated compared with Dox alone.
CONCLUSION
Sob with Dox exhibited an antitumor synergistic effect on leukemia P388, and the cardiotoxicity of Dox was reduced by Sob.
Zotero 插件